BioXell (SIX: BXLN) has recently announced changes in its clinical and pre-clinical development plans, and has initiated organizational changes. These changes include:

• Termination or placement on hold of all research activities with regards to the Company's Vitamin D3 platform (Elocalcitol and BXL746) and TREM technologies
• Appointment of Niels Ackermann, BioXell's Chief Financial Officer, as the Company’s new Chief Executive Officer as of April 27, 2009
• Initiation of a redundancy procedure in order to align the Company’s internal organization and resources with its reduced product R&D pipeline and activities
• Focus future development efforts on the progression of its preclinical monoclonal antibody BXL1H5 for the treatment of chronic pain

Based on these changes, we would like to inform our website users that specific sections of this site, notably the product pipeline and technology section, are out of date and will be updated following the Company’s full assessment of its strategic options.

For the latest information, please visit the media section.

BioXell Analyst Presentation 2009, Webcast

September 2009
Interim financial results

9-11 September 2009
Rodman and Renshaw Annual Global Investment Conference, New York 

2-4 November 2009
Bio-Europe 2009, Vienna